Qingdao Huanghai Biological Pharmaceutical Sets Up Sodium Alginate Production Base
This article was originally published in PharmAsia News
Executive Summary
Qingdao Huanghai Biological Pharmaceutical, a subsidiary of Qingdao Huanghai Pharmaceutical, recently hosted a ground-breaking ceremony for its medical sodium alginate production project in Jiaozhou city, Qingdao. With a total investment of RMB 300 million, the 66,072-square-meter facility began construction in February and is scheduled for operation at year end. The first phase, with RMB 100 million funding, will involve setting up a raw pharmaceutical materials production workshop, office buildings, warehouses and auxiliary facilities. Huanghai Biological will mainly produce azelnidipine and sodium alginate, and target a production value of RMB 1 billion for sodium alginate within three years. Analysts see the move significant since the plant represents China's first sodium alginate manufacturing facility for medical use, indicating the market potential for local biopharmaceutical industry development. (Click here for more - Chinese Language)